These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9639444)

  • 41. Pilot study of high dose fenretinide and vitamin A supplementation in bladder cancer.
    Decensi A; Bruno S; Torrisi R; Parodi S; Polizzi A
    Eur J Cancer; 1994; 30A(12):1909-10. PubMed ID: 7880629
    [No Abstract]   [Full Text] [Related]  

  • 42. Ocular signs and symptoms and vitamin A status in patients with cystic fibrosis treated with daily vitamin A supplements.
    Ansari EA; Sahni K; Etherington C; Morton A; Conway SP; Moya E; Littlewood JM
    Br J Ophthalmol; 1999 Jun; 83(6):688-91. PubMed ID: 10340977
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide.
    Formelli F; Cavadini E; Luksch R; Garaventa A; Villani MG; Appierto V; Persiani S
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):655-65. PubMed ID: 18066548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fenretinide in breast-cancer chemoprevention (review).
    Decensi A; Formelli F; Torrisi R; Depalo G; Costa A
    Oncol Rep; 1994 Jul; 1(4):817-24. PubMed ID: 21607448
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Topography of cone dark adaptation deficits in age-related maculopathy.
    Gaffney AJ; Binns AM; Margrain TH
    Optom Vis Sci; 2011 Sep; 88(9):1080-7. PubMed ID: 21705940
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
    Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
    Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rod and cone function in the Nougaret form of stationary night blindness.
    Sandberg MA; Pawlyk BS; Dan J; Arnaud B; Dryja TP; Berson EL
    Arch Ophthalmol; 1998 Jul; 116(7):867-72. PubMed ID: 9682699
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of N-(4-hydroxyphenyl)-all-trans-retinamide in rats.
    Swanson BN; Zaharevitz DW; Sporn MB
    Drug Metab Dispos; 1980; 8(3):168-72. PubMed ID: 6104581
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia.
    Chiesa F; Tradati N; Marazza M; Rossi N; Boracchi P; Mariani L; Formelli F; Giardini R; Costa A; De Palo G
    J Cell Biochem Suppl; 1993; 17F():255-61. PubMed ID: 8412202
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dark adaptation in hyperprolactinemic women.
    Fulton AB; Greenwood V; Hansen RM; McGill MG; Russell RM; Deuster PA; Kappelman MC
    Invest Ophthalmol Vis Sci; 1989 Jun; 30(6):1177-80. PubMed ID: 2732032
    [TBL] [Abstract][Full Text] [Related]  

  • 51. N-(4-hydroxyphenyl)retinamide (fenretinide) induces retinol-binding protein secretion from liver and accumulation in the kidneys in rats.
    Schaffer EM; Ritter SJ; Smith JE
    J Nutr; 1993 Sep; 123(9):1497-503. PubMed ID: 8360775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
    Formelli F
    J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.
    Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM
    PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The metabolite N-4-methoxyphenylretinamide is a major determinant of fenretinide induced decline of plasma insulin-like growth factor-1.
    Torrisi R; Pensa F; Fontana V; Costa A; Decensi A
    Eur J Cancer; 1995; 31A(3):420-1. PubMed ID: 7786612
    [No Abstract]   [Full Text] [Related]  

  • 55. Prolonged rod dark adaptation in retinitis pigmentosa.
    Alexander KR; Fishman GA
    Br J Ophthalmol; 1984 Aug; 68(8):561-9. PubMed ID: 6743626
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hyperoxia, hyperglycemia, and photoreceptor sensitivity in normal and diabetic subjects.
    Kurtenbach A; Mayser HM; Jägle H; Fritsche A; Zrenner E
    Vis Neurosci; 2006; 23(3-4):651-61. PubMed ID: 16962009
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemia.
    Morad SA; Davis TS; Kester M; Loughran TP; Cabot MC
    Leuk Res; 2015 Oct; 39(10):1071-8. PubMed ID: 26220867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hydrolysis of 4-HPR to atRA occurs in vivo but is not required for retinamide-induced apoptosis.
    Chapman JS; Weiss KL; Curley RW; Highland MA; Clagett-Dame M
    Arch Biochem Biophys; 2003 Nov; 419(2):234-43. PubMed ID: 14592467
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells.
    Golubkov V; Garcia A; Markland FS
    Anticancer Res; 2005; 25(1A):249-53. PubMed ID: 15816545
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines.
    Kalemkerian GP; Slusher R; Ramalingam S; Gadgeel S; Mabry M
    J Natl Cancer Inst; 1995 Nov; 87(22):1674-80. PubMed ID: 7473815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.